Patent: 10,010,585
✉ Email this page to a colleague
Summary for Patent: 10,010,585
Title: | Methods of treating vestibular schwannoma and reducing hearing or neurite loss caused by vestibular schwannoma |
Abstract: | Methods to reduce the proliferation of vestibular schwannoma (VS) cells and/or provide neuroprotection to reduce the risk of sensorineural hearing loss (SNHL), vestibular dysfunction and facial nerve paralysis in subjects with VS. The methods can include one or more of decreasing TNF-.alpha. activity or expression; decreasing NF-.kappa.B expression or activity; decreasing COX-2 expression or activity; administering FGF2; decreasing HGF expression or activity; or decreasing c-Met expression or activity. |
Inventor(s): | Stankovic; Konstantina (Boston, MA), Dilwali; Sonam (Dallas, TX) |
Assignee: | Massachusetts Eye and Ear Infirmary (Boston, MA) |
Application Number: | 14/741,332 |
Patent Claims: | see list of patent claims |
Details for Patent 10,010,585
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2034-06-16 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2034-06-16 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2034-06-16 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | ⤷ Try a Trial | 2034-06-16 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 02/01/2007 | ⤷ Try a Trial | 2034-06-16 |
Immunex Corporation | ENBREL MINI | etanercept | Injection | 103795 | 09/14/2017 | ⤷ Try a Trial | 2034-06-16 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |